Fig. 3From: The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mgAdapted from Astrup et al. [35]Proportion of individuals with prediabetes in the ITT population at randomisation and week 20. Individuals included are those with valid assessment at the start and the end of the 20-week trial period. *P = 0.007 vs placebo. †P = 0.008 vs orlistat. ‡P ≤ 0.0001 vs placebo or orlistatBack to article page